Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440686 | 0.88 | ERN1 (0.44) | ERN1TAAR1ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL1645590 | 0.88 | ERN1 (0.62) | ERN1TAAR1ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL1459113 | 0.86 | ERN1 (0.43) | ERN1TAAR1ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL15348517 | 0.86 | ERN1 (0.66) | ERN1TAAR1ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL13982472 | 0.82 | ERN1 (0.44) | ERN1TAAR1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL15109407 | 0.80 | TAAR1 (0.42) | ERN1TAAR1CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL16056054 | 0.79 | NQO2 (0.42) | ERN1NQO2 | |
| SCHEMBL28091439 | 0.79 | TAAR1 (0.47) | ERN1TAAR1ALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL16562821 | 0.78 | GRM5 (0.33) | ERN1TAAR1ALDH1A1HDAC1PRKDC | |
| SCHEMBL15487329 | 0.78 | NPC1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118909249-A | Preparation process of fluorine-containing soluble polyimide | 矽时代材料科技股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-118909249-A | Preparation process of fluorine-containing soluble polyimide | 矽时代材料科技股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118909249-A | Preparation process of fluorine-containing soluble polyimide | 矽时代材料科技股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2024-04-16 | — | — | US | disclosed |
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-02-29 | — | — | US | disclosed |
| CN-111757883-B | Novel inhibitors of bacterial glutaminyl cyclase for the treatment of periodontal disease and related diseases | 弗劳恩霍夫应用研究促进协会 | 2024-02-13 | — | — | CN | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-3872061-B1 | 1-PHENYL-2-PHENYLETHANE DERIVATIVE | KAO CORP (JP) | 2023-12-27 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1698624-A1 | PHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-5773456-A | EMPHYSEMA, RHEUMATOID ARTHRITIS AND PANCREATITIS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5464852-A | Used in treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5380737-A | Enzyme inhibitors | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0542371-A1 | Saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958871-B2 | Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases | GMPS, GLS, QPCT | ERN1 3177/4885TAAR1 4244/4885ALDH1A1 3726/4885 |
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, NUAK1, NUAK2 | ERN1 525/4885TAAR1 1337/4885ALDH1A1 4504/4885 |
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | ERN1 1226/4885TAAR1 400/4885ALDH1A1 519/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | ERN1 2323/4885TAAR1 1932/4885ALDH1A1 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.